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Fibroblast growth factor 21 (FGF21) is a protein highly synthesised in the liver that exerts 
paracrine and endocrine control of many aspects of energy homeostasis in multiple tissues. 
In preclinical models of obesity and type 2 diabetes, treatment with FGF21 improves glucose 
homeostasis and promotes weight loss, and as a result FGF21 has attracted considerable 
attention as a therapeutic agent for the treatment of metabolic syndrome in humans. An 
improved understanding of the biological role of FGF21 may help to explain why its 
therapeutic potential in humans has not been fully realised. This review will cover the 
complexities in FGF21 biology in rodents and humans, with emphasis on its role in the 




FGF21 – a novel metabolic regulator 
Fibroblast growth factor 21 (FGF21) is a hormone shown to play a key role in the regulation 
of energy homeostasis in both preclinical studies and man. Consequently, leveraging the 
broad metabolic effects of FGF21 for the treatment of metabolic syndrome has received 
significant interest from the pharmaceutical industry.  The therapeutic potential of FGF21 was 
first recognised when it was reported that FGF21 reduces plasma glucose and triglycerides in 
mouse models of obesity, and that overexpression of FGF21 provided resistance to body 
weight gain in mice on a high fat diet (1,2). However, contemporary data challenge existing 
concepts, and many facets of FGF21 biology remain divisive and/or poorly understood. 
Furthermore, only some of the metabolic effects characteristic of FGF21 action in preclinical 
studies using laboratory rodents are evident in humans, representing a significant challenge 
for the translational potential of engineered FGF21-based therapeutics. Indeed, several 
human clinical trials using FGF21 analogues have failed to observe meaningful blood glucose 
lowering and insulin sensitizing effects, although significant improvements in dyslipidaemia 
and markers of fatty liver disease have been reported (see text Box 1). Consequently, FGF21 
biology is rapidly moving into new arenas – control of macronutrient preference, providing 
protection from nonalcoholic steatohepatitis and nonalcoholic fatty liver disease 
(NASH/NALFD respectively), or more broadly as a biomarker for disease. Hence, there is a 
need to go back to the natural biology of FGF21 with the objective of better understanding 
its role in these diseases with the aim of maximizing its therapeutic potential.  
 
Box 1 - Clinical trials with FGF21 analogues 
Long-acting FGF21 analogues have been utilised in several human clinical trials showing improvement in some, 
but not all aspects of the metabolic syndrome. In overweight/obese patients with type 2 diabetes (T2D), 
treatment with LY2405319, a variant of FGF21, produced improvements in fasting insulin levels but only a 
modest, nonsignificant fasting glucose lowering effect (3). Similarly, treatment with PF-05231023, a long-acting 
FGF21 analogue, and Pegbelfermin (BMS-986036), a PEGylated human FGF21 analogue, had no effects on 
glycaemic control and HbA1c in overweight/obese patients with T2D (4-6). The effects of those analogues on 
body weight was variable, with no change observed after 12 weeks of treatment with BMS-986036 (6), a small 
reduction of 1.8% in response to 4 weeks of LY2405319 (3) and a modest loss of 5-6% after 4 weeks on PF-
05231023 (4). However, all trials reported improvements in dyslipidaemia with significant reductions in plasma 
triglycerides (up to 50%) and improved plasma lipoprotein profile (reductions of total cholesterol by up to 20% 
and LDL by ~30%, and increases in HDL by up to 25%). Overall, the effects of FGF21 analogues on aspects of 
glucose control and body weight loss are modest at best and cannot match the improvements observed with 
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current pharmacological and lifestyle changes-based treatments targeting weight loss and/or improvement of 
b-cell function and insulin sensitivity in patients with T2D (7). However, the therapeutic potential of FGF21 
analogues may be realised when combined with other current therapies targeting glycaemic control or as a 
monotherapy to improve plasma lipid profiles and for the treatment of NASH/NAFLD (8) (see text Box No 4).  
 
Since its initial isolation from liver in 2000 (9), FGF21 has been shown to be widely expressed 
in metabolic organs including the gastrointestinal tract, adipose tissue and pancreas (10). 
FGF21 has been demonstrated to cross the blood-brain barrier in rats, is detectable in human 
cerebrospinal fluid [CSF], and there is a linear relationship between serum and CSF levels 
(11,12). Furthermore, FGF21 biology demonstrates circadian rhythmicity – serum 
concentrations exhibit a clear diurnal rhythm, and dysregulation correlates with obesity-
induced lipid disorders (13). Despite this and its widespread distribution, various strains of 
FGF21 knockout (KO) mice show variable effects on body weight and composition, and 
circulating glucose. This in itself is controversial, with some groups reporting fasting 
hypoglycaemia – a possible consequence of the age of the animals and/or the fasting 
schedules (14-16). Although these animals showed normal growth, development and fertility, 
subsequent studies have suggested that FGF21 may have adverse effects on these processes 
but is not essential (1,16-20). Thus, the physiological role of FGF21 is in the adaption to altered 
metabolic demand, for example in times of stress; levels of FGF21 are increased under a 
variety of physiological interventions and pathogenic events, including starvation (acutely in 
mice, chronically in humans), obesity (in mice and humans) and exercise (in mice and humans) 
(17,21-23). Furthermore, the effects of treatment with exogenous FGF21 are pleiotropic. Here 
we will explore the complexities in FGF21 biology and physiology in animal models and adult 
humans, its pharmacology and metabolic actions from a preclinical and clinical perspective.   
 
Box 2 - The biology of FGF21  
FGF21 (gene ID 56636) is located on chromosome 7, contains three coding exons, which produces a single 
transcript, a pre-protein of 210 amino acids (aa) with a N-terminal signal peptide of 22aa. In humans, FGF21 
(gene ID 26291) also contains three exons, however, this produces two transcripts via alternative promoters, 
both of which encode a pre-protein of 208aa, including a 28aa signal peptide. The sequence identity is circa 80%. 
Functionally the FGF superfamily is grouped into three subfamilies; intracellular FGFs which lack a signal peptide, 
FGFs which lack heparin sulphate binding capacity, indicating the potential for their escape into the circulation, 
exerting systemic action, and FGFs with a high heparin sulphate binding capacity, thus potentially act in an 
autocrine/paracrine manner (24). At target tissues, FGF21 binds to and activates members of the FGFR 
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superfamily of receptor tyrosine kinases (25). FGFR activation by FGF21 in vitro and in vivo is dependent on 
obligate co-receptor bKlotho (KLB), an FGFR-binding, single-pass transmembrane protein (2,26). Preference for 
both FGFR1c- and FGFR3c-KLB complexes has been demonstrated, so given the widespread expression of the 
FGFRs, tissue specificity and sensitivity is mainly governed by the presence and relative expression of KLB (27-
30). Activation of these receptor complexes by FGF21 leads to a plethora of rapid signaling events (31,32).  
 
Box 3 - Tissue specific physiology  
The highest level of FGF21 expression in the adult mouse is the liver. The liver is regarded as the major source 
of circulating FGF21; liver-specific deletion of FGF21 created by crossing FGF21-floxed mice (FGF21fl/fl) with an 
albumin-Cre line results in dramatic reductions in circulating FGF21, and the increase typically observed in 
response to fasting is lost (33). Peroxisome proliferator-activated receptor α (PPARα), a nuclear receptor 
activated by fatty acids, is required for the normal adaptive response to starvation (34). Mice lacking PPARα 
accumulate hepatic triglyceride and become hypoketonemic during fasting and starvation (35-37). A 
downstream target of PPARα, hepatic FGF21 increases in response to dietary manipulation (fasting, ketogenic 
diet) and is rapidly suppressed by refeeding in mice (17,18,38). Indeed, FGF21 was offered as the “missing link” 
in the biology of fasting, inducing adipose tissue lipolysis, liver ketogenesis and metabolic adaptation to the 
fasting state (39). Furthermore, FGF21-/- mice showed impaired adaptation to ketosis, whilst adenoviral 
knockdown of FGF21 in the liver caused mice consuming a ketogenic diet to display fatty livers, 
hypertriglyceridemia and reduced fat oxidation (15). Having established that FGF21 was critical to the adaptive 
metabolic response to starvation in mice, data emerged demonstrating the induction of FGF21 in response to 
amino acid deprivation and protein restriction. This is mediated by the eukaryotic translation initiation factor 
(EIF) 2α-activating transcription factor (ATF)4-CHOP axis of the ER stress response in mice (40). Mice consuming 
diets deficient in methionine, leucine and alanine demonstrated increased serum FGF21 concentrations (40-42). 
Furthermore, consumption of methionine/choline-deficient diets in mice results in NASH and is associated with 
increased hepatic expression and serum levels of FGF21. FGF21 knock out mice have an exacerbated phenotype 
on this deficient diet, in part due to attenuated activation of fatty acid oxidation, as well as increased expression 
of genes involved in lipid uptake and synthesis (43,44). Pharmacological treatment of these mice with FGF21 
resolved the phenotype.  
 
Box 4 - Lessons from rodent models provide a liver-centric view.  
One of the many paradoxes in the FGF21 field is that hepatic FGF21 expression is also increased in response to 
nutrient excess, a process described in rodents and humans that is likely mediated via the carbohydrate response 
element binding protein (ChREBP) that may participate in the pathogenesis of NAFLD (9,21,45-47). FGF21 levels 
in liver and adipose tissue are also elevated in db/db obese diabetic mice as compared with their lean db/+ 
littermates, in adult male rhesus macaque monkeys chronically maintained on a high fat diet (HFD), and in serum 
in overweight/obese humans (48,49). Serum FGF21 is positively correlated with adiposity, fasting circulating 
insulin and triglycerides – logistic regression analysis demonstrated an independent association between serum 
FGF21 and metabolic syndrome (48). It was subsequently shown that in response to carbohydrate intake, the 
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liver produces FGF21 to selectively supress sugar intake by acting on the paraventricular nucleus of the 
hypothalamus (50) (see the CNS section below). Therefore, FGF21 is a key regulator of the nutritional state of 
the organism and co-ordinates the adaptive metabolic response. Whilst the induction of FGF21 in response to 
changes in macronutrient ingestion is important for metabolic adaptation. Whether the liver is an important site 
of FGF21 action, however, is debatable. ERK1/2 phosphorylation and mRNA expression of immediate early gene 
markers downstream of the FGFR-KLB complex that are readily observed in adipose tissue in response to 
treatment with FGF21 are not so apparent in liver. However, Akt phosphorylation in the liver is reported in lean 
and ob/ob animals, in which FGF21 suppresses glucose production and increases insulin sensitivity (51). 
Furthermore, other groups have shown that FGF21 does induce FRS2 and ERK1/2 phosphorylation in the liver of 
both lean and obese animals – with a time course and dose response similar to adipose tissue (28,52). 
Furthermore, in HepG2 cells, FGF21 induces ERK1/2 phosphorylation providing evidence that FGF21 may act 
directly on the hepatocyte (53). Indeed, FGF21 exerts dual effects on hepatic energy metabolism, modulating 
net flux through both carbohydrate and fat metabolism (54) (see Seasonal Lessons section below). Therefore, 
by stimulating hepatic fat oxidation, FGF21 may be an attractive target for protection from increased hepatic 
lipid content and insulin resistance that frequently accompanies obesity and T2D. Indeed, targeting hepatic fat 
accumulation and insulin resistance is a major therapeutic approach to the management of NAFLD and NASH, 
two of most prevalent forms of liver disease that are closely associated with obesity and T2D (55).  An engineered 
variant of FGF21 has been shown to attenuate NASH progression in an animal model of NASH (56). Whereas a 
clinical phase 2 trial (NCT02413372) with a recombinant FGF21 in NASH patients significantly reduced hepatic 
fat content and biomarkers of fibrosis (57). Therefore, FGF21 may be emerging as a new class of drug for the 
treatment of fatty liver disease. 
 
Adipose tissue: a key determinant of FGF21 action 
Adipose tissue is a highly dynamic organ, which in response to the internal environment, 
undergoes extensive remodelling.  Caloric restriction, for example, promotes mitochondrial 
biogenesis and fatty acid oxidation, whereas white adipose tissue rapidly expands in response 
to an obesogenic diet by increasing lipid storage and the number of adipocytes (58,59).  These 
are evolutionary protectives mechanisms to ensure adequate glucose supply for the brain, 
and delivery of free fatty acids (FFA) and amino acids to peripheral organs. Adipose tissue is 
known to play a crucial role in the buffering of diet-derived FFA in the post-prandial period 
(60). If this role, however, is impaired due to a disruption of insulin signaling in adipose tissue, 
excessive lipids accumulate in other tissues such as liver and skeletal muscle, and may result 
in the development of insulin resistance (61). Therefore insulin-sensitising agents targeting 
adipose tissue are in high demand.  
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Initially, FGF21 was shown to stimulate glucose uptake in 3T3-L1 adipocytes via glucose 
transporter 1 (GLUT1) (2). An effect dependent on ERK1/2 and ELK-1 signaling (27). Indeed, 
acute administration of FGF21 to ob/ob and db/db mice or to mice with diet-induced obesity 
rapidly improved insulin sensitivity and decreased plasma glucose levels (51,62). However, 
the effect on glucose uptake and GLUT1 in adipose tissue was not apparent in chronically 
treated animals, despite lower blood glucose, which was achieved via the suppression of 
hepatic glucose production (63). Subsequently, FGF21 was shown to increase glucose uptake 
in BAT and WAT in lean mice, suggesting a differential response to FGF21 dependent on 
metabolic status and/or adiposity (64).  
 
Chronic treatment of mice with FGF21 did, however, increase energy expenditure and result 
in weight loss (65,66), and, as a consequence, improve insulin sensitivity. However, the role 
of uncoupling respiration via activation of UCP1 to the pharmacological effects of FGF21 is 
not completely resolved. Studies using UCP1-KO mice have shown that several but not all 
metabolic endpoints are UCP1 independent (67,68). Whereas UCP1-mediated thermogenesis 
was not required for FGF21 to lower body weight, improve glycaemic control or reduce 
circulating insulin and lipids (67,68), the ability of FGF21 to promote postprandial glucose 
tolerance was impaired in the absence of UCP1 in obese, glucose intolerant mice (69). On the 
other hand, the ability of FGF21 to augment energy expenditure was significantly attenuated 
in one (67) but not another study (68). Further research is required to elucidate these 
seemingly contradictory findings.  
 
FGF21 signaling in adipose tissue was essential for the acute insulin-sensitizing effects of 
FGF21, specifically in brown adipocytes, but not for its effects on body weight – this effect 
was via non-adipose tissues (70). Interestingly, BAT is present in humans and correlates 
negatively with BMI and fasting blood glucose levels (71). However, humans possess relatively 
less BAT when compared to rodents which may account for the attenuated glucose lowering 
responses to FGF21 treatment observed in human clinical trials (Please see text Box 1). Given 
the variable distribution of BAT in different populations (e.g. more commonly associated with 
women and lean individuals) (71), further targeted clinical work is required to determine the 
contribution of BAT in the metabolic responses to FGF21 in human subjects. 
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The increase in circulating FGF21 in response to fasting resulted in the hypothesis that FGF21 
induces lipolysis in adipose tissue. Indeed, this was demonstrated in vivo (15,18). However, in 
vitro, FGF21 was shown to be a potent repressor of lipolysis in mouse (and human) adipocytes 
(72,73). Acute doses and chronic treatment with FGF21 reduce FFA (66,72). Further work is 
required to dissect this duality and determine the precise role of FGF21 in lipolysis.  At target 
tissues, FGF21 binds to and activates members of the FGFR superfamily of receptor tyrosine 
kinases (25). FGFR activation by FGF21 is dependent on obligate co-receptor bKlotho (KLB), 
an FGFR-binding, single-pass transmembrane protein (2,26). Mice lacking the FGFR1 receptor 
in adipose tissue show attenuated responses to the metabolic effects of FGF21 (74,75). 
Similarly, mice with complete or adipose-specific ablation of KLB are resistant to acute insulin-
sensitising and glucose-lowering effects of FGF21 (74,76). In mice, KLB expression is seen in 
adipose tissue, the liver, gall bladder, colon and pancreas, as well as the suprachiasmatic and 
paraventricular nuclei of the hypothalamus, and discrete regions of the brain stem (10,19). 
Indeed, over-expression of KLB in adipose tissue sensitises mice to endogenous FGF21 and 
offers protection from diet-induced obesity (29). It was subsequently shown that KLB levels 
are markedly decreased in white adipose tissue during diet-induced obesity. Interestingly, 
TNF-α represses KLB expression and impairs FGF21 action in adipocytes in vitro, a mechanism 
mediated by TNF-α induced inflammation as the insulin-sensitizing anti-inflammatory drug 
rosiglitazone restored KLB levels (28). Furthermore, high glucose represses KLB expression 
and impairs FGF21 action in mouse pancreatic islets (77). Therefore, the concept of 
endogenous “FGF21 resistance” has been raised – the biology of which requires further 
investigating as impairment of the pharmacological actions of FGF21 has not been shown. 
Furthermore, a hugely interesting aspect of FGF21 biology is the recent evidence from our 
animal studies (see Seasonal Lessons below) that the actions of FGF21 are enhanced in states 
of increased adiposity. Therefore, increasing KLB expression would be an interesting 
therapeutic option. Indeed, GLP-1 analogues and glitazones increase KLB expression in vivo 
(78,79) and may therefore increase FGF21 sensitivity, contributing to further metabolic 
improvements. On the other hand, maintenance of KLB protein expression in white adipose 
tissue does not alleviate impaired FGF21 signaling in this tissue or increase FGF21 sensitivity 
in vivo (80). Despite these contradictory results on the role of KLB, adipose tissue appears to 




The CNS: the final frontier for FGF21 
The CNS integrates a vast array of signals from the periphery to regulate feeding behaviour 
and energy homeostasis - dysregulation results in obesity and T2D. These signals (hormones 
and nutrients, plus their by-products) act directly on the hypothalamus, the hindbrain or 
peripheral neurones which terminate in the nucleus of the solitary tract (NTS)(81). As noted 
above, FGF21 can cross the rodent blood-brain barrier (11) and is detectable in human 
cerebrospinal fluid with a linear relationship between serum and CSF levels suggesting that 
circulating FGF21 is the source of central FGF21 (12) – this is key for therapeutics whose 
primary targets are the CNS. The FGFR subtypes are widely expressed in the CNS, whilst KLB 
is highly expressed in the suprachiasmatic nucleus in the hypothalamus and in a number of 
hindbrain regions (19). The film autoradiography/in situ hybridization strategy used by 
Bookout et al 2013 (19) does not exclude the possibility that KLB might be expressed at lower 
levels or in isolated cells in other regions of the brain, indeed Liang et al., 2014 (14) reported 
Western blot and immunostaining of KLB in the paraventricular nucleus of the hypothalamus 
of mice (82).  Overexpression of FGF21 lowers circulating levels of insulin and activation of 
the HPA axis, and suppresses the reproductive axis (14,19,20). Furthermore, ICV injection of 
FGF21 increases sympathetic nerve activity in BAT – this effect is attenuated in mice lacking 
central KLB. Interestingly, treatment with a generic beta-blocker attenuated the effects of 
centrally administered FGF21 but not of FGF21 delivered peripherally. To exert its effects on 
energy expenditure, weight loss and cholesterol in mouse models of obesity, central action 
of FGF21 may be required (83,84).  
 
More recently, FGF21 has been shown to suppress the consumption of simple sugars and non-
caloric sweeteners via actions on hypothalamic neurons (50). In addition, FGF21 reduces 
alcohol preference in mice, whilst stimulating water drinking behaviour (85,86). The latter 
effect is inhibited by β-adrenergic receptor antagonists, suggesting a critical role of the 
sympathetic nervous system in mediating the effects of FGF21 in those responses. The 
emergence of FGF21 as a regulator of food preference both in rodents and humans, along 
with its role in metabolic regulation, raises the interesting prospect of its therapeutic 





Seasonal lessons  
Whilst the ready availability of genetic tools have resulted in mice being the dominant animal 
model in recent years for studying mechanisms underlying energy metabolism, their high 
metabolic rate, rapid growth and dependence on brown fat for thermogenesis when 
maintained under standard housing limits their translational value (87,88).  Most mammals 
are seasonal in that they display profound annual cycles in appetite, fat metabolism, 
reproduction and body weight (89). Investigating the function of FGF21 in this context 
provides different insights into its biology, because deposition of body fat does not result in 
metabolic dysfunction. Thus, it becomes possible to study the effects of FGF21 in healthy 
obesity without the complications of the development of insulin resistance or NAFLD.  
Siberian hamsters (Phodopus sungorus) have been widely used as a seasonal rodent model 
because they can be readily maintained in animal facilities, and seasonal cycles in energy 
metabolism generated simply by changing the environmental daylength (90).  Under long day 
conditions, typically with the light phase being 14 hours of light per day or more, these 
hamsters become hyperphagic and rapidly gain body weight, whereas under short days with 
the light phase being 8 hours per day or shorter they reduce their food consumption, and lose 
up to 30% of body weight over the course of a few months.  This primarily reflects loss of 
visceral adipose depots, though significant loss of lean mass also occurs (91).  Thus, studies in 
this kind of seasonal mammal can address the role of FGF21 in natural situations of weight 
loss and gain, and provide the opportunity to investigate mechanisms of action of FGF21 in 
naturally occurring states of adiposity and leanness (Figure 1). 
 
When exposed to short photoperiods, male hamsters show a significant increase in circulating 
FGF21 by 8 weeks that correlates with significant weight loss and decrease in epididymal fat 
pad mass at this time point (92).  Western blot analysis reveals that whilst FGF21 is detectable 
in liver, white fat, brown fat and in muscle (gastrocnemius), only in the liver and brown fat 
are there significant increases in FGF21 concentrations as hamsters progress into short 
photoperiods (92). The close correlation between liver and plasma FGF21 concentrations 
supports the argument that the liver is the predominant source of circulating FGF21.   Similar 
observations have been made in another seasonal species, the thirteen-lined ground 
squirrel (Ictidomys tridecemlineatus). Serum FGF21 concentrations increase in squirrels 
exposed to short photoperiods in the fall, the increase being greater in animals in torpor than 
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during bouts of arousal in winter, and concentrations then fall again as photoperiod is 
increased in the following spring (93). Again these circulating FGF21 concentrations closely 
correlate with expression of FGF21 mRNA in the liver, as assessed by quantitative PCR (93).  A 
key question is whether the increases in circulating FGF21 contribute to the behavioural and 
physiological adaptations induced by short photoperiod. Chronic infusion of hamsters 
maintained in summer long day photoperiods with FGF21 results in some aspects of the short 
day response, for example decreased appetite and decreased body weight, reduced weight 
of epididymal fat depots, and a decrease in respiratory exchange ratio that would be 
consistent with increased whole body fat oxidation (94,95) (Figure 1). These effects of FGF21 
infusion were lost in hamsters tests after 12 weeks exposure to short day winter photoperiods 
at which point they had reached the nadir of the seasonal body weight cycle, and effects were 
also attenuated in ageing male Siberian hamsters that had reduced body weight (94). These 
observations in naturally-altered states of adiposity support the view that a major target of 
this hormone is white adipose tissue.  This conclusion is supported by analysis of perirenal 
and subcutaneous white adipose tissue in hamsters treated with FGF21. For example, 
expression of fgfr1c and bklotho are upregulated in FGF21-treated hamsters, triglyceride 
lipase is increased and triglyceride content are reduced, and signal transduction events 
downstream of FGFR1c-bKlotho receptors including ERK1/2 phosphorylation are increased 
(94).  
 
Although these studies in hamsters indicate that white adipose tissue is the main determinant 
of whole-body responsiveness to FGF21, they also identify additional targets (Figure 1). The 
thermogenic genes ucp1 and dio2 (deiodinase 2) were significantly upregulated in 
interscapular brown fat (94), which likely underlies increases in whole body energy 
expenditure detected in hamsters infused with FGF21 (95).  Hepatic energy metabolism is also 
affected such that fatty acid oxidation is favoured over carbohydrate oxidation. Indeed, FGF21 
infusion reduced pyruvate dehydrogenase activity (PDC, the enzyme that catalyses the rate 
limiting step in glucose oxidation) and acetylcarnitine accumulation (an index of reduced flux 
through PDC), but increased long-chain acylcarnitine content (suggesting an increased flux 
through b-oxidation) in the liver (54). These dual effects of FGF21 on hepatic energy 
metabolism were mediated by increased protein abundance of PDK4 (a negative regulator of 
PDC), the phosphorylated (inhibited) form of acetyl-CoA carboxylase (a negative regulator of 
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delivery of fatty acids into the mitochondria), and the transcriptional co-regulators of energy 
metabolism PGC1a and SIRT-1 (54).  
 
Intriguingly, it appears likely that systemic FGF21 may also target the brain.  There are 
consistent suppressive effects of FGF21 on appetite in hamsters (94,95). This is in contrast to 
studies in mice where FGF21 treatment has been associated with increased food intake, 
presumably a compensatory response to enhanced whole body energy expenditure (96). 
Whilst these effects do not necessarily indicate a direct action centrally, perhaps reflecting 
altered signaling from other peripheral signals to the brain, in hamsters the appetite-
suppressing actions of FGF21 are associated with decreased levels of peripheral anorectic 
signals such as leptin and insulin (94).  Importantly, peripheral FGF21 induced upregulation of 
dio2 in the hamster hypothalamus (97,98).  This enzyme that is highly expressed in 
hypothalamic tanycytes converts the thyroid hormone precursor thyroxine into the 
biologically active form tri-iodothyronine (T3).  Altered local concentrations of T3 in the 
hypothalamus are considered to be the main driver of season cycles of appetite and energy 
expenditure (99,100), so this is a likely pathway of action for FGF21 regulating food intake in 
hamsters.  Further evidence from studies in mice for central actions of FGF21 is considered in 
a previous section. The distribution of bKlotho has not yet been demonstrated in the hamster, 
but FGFR1c is expressed in the tanycyte cell layer of hamsters (101). Intracerebroventricular 
treatment of hamsters with an anti-FGFR1c monoclonal antibody that may mimic the actions 
of FGF21 decreases appetite, increases whole body energy expenditure and fat oxidation, and 
induces weight loss (101).  Given the recent evidence that tanycytes are in effect part of the 
blood brain barrier in the hypothalamus and are critical in sensing nutrients and peripheral 
hormones (102), this is a likely target for peripheral FGF21 that requires further validation. 
 
The catabolic effect of FGF21 are consistent with a role in facilitating the hypophagic and 
lipolytic state that occurs in hamsters in short days, but it should be borne in mind that the 
circulating concentrations of FGF21 delivered in these studies is in the supraphysiological 
range (95).   Nelson et al tested the role of FGF21 in generating seasonal metabolic responses 
by overexpressing FGF21 in ground squirrels using an adenoviral approach (103).  This 
increased circulating FGF21 was associated with decreased circulating insulin and FFA 
concentrations, but was not sufficient to induce winter torpor bouts (93).  It is clear from 
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analysis of hypothalamic gene expression that hamsters do not respond to the decrease in 
circulating leptin that reflects reduced caloric intake and increased lipolysis in short days with 
compensatory hyperphagia (104).  Perhaps the role of FGF21 in short days then is to promote 
metabolic adaptation to negative energy balance, rather than be an underlying driver of 
winter physiology.  Given the efficacy of FGF21 in hamsters in an obese but not metabolically 
compromised state, perhaps the optimal strategy for clinical use of FGF21 in humans would 
be in obese populations, particularly those with risk factors for cardiovascular and fatty liver 
diseases, prior to the development of T2D. 
  
Advances in the biology of FGF21 – a human perspective  
FGF21 has been implicated in a number of clinical and non-clinical conditions in humans 
including the metabolic syndrome and T2D, hepatic liver disease and metabolic regulation 
during exercise (48,105-108). However, there are still unanswered questions remaining 
around its biological role in humans as a starvation hormone, exercise-induced myokine and 
postprandial regulator of metabolism, in particular its link to insulin action and the metabolic 
syndrome.  
 
FGF21 is often described as a key hormone in the biology of fasting in a variety of animal 
models. However, in humans, neither ketogenic diets (up to 3 months) nor short-term fasting 
(up to 48h) increase serum FGF21 levels (109). Interestingly, elevations in FGF21 in humans 
are seen following prolonged fasting (7-10 days); a possible consequence of the divergent 
metabolic rates and adaptations to fasting between the species (22,110). Since the ketogenic 
response in humans precedes the induction of FGF21 and ketogenic diets are associated with 
a reduction in circulating levels of FGF21, it appears that induction of FGF21 is not required 
to stimulate ketosis in humans but may serve to facilitate metabolic adaptations to prolonged 
periods of food deprivation (109).  
 
Importantly, recent evidence suggests that FGF21 is an insulin-dependent postprandial 
hormone in humans (Figure 2). Indeed, short-term dietary carbohydrate, but not fat 
interventions, markedly increase the fasting circulating levels of FGF21 (47,111). 
Furthermore, FGF21 secretion has been shown to respond to oral carbohydrate consumption, 
with fructose reported to increase plasma levels of FGF21 in humans to a greater extent than 
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glucose (112). Fructose ingestion was associated with elevated levels of circulating insulin, 
albeit to a lesser extent than glucose ingestion, which makes it difficult to dissociate its insulin-
dependent and -independent effects. Using oral glucose tolerance tests and a combination of 
hyperglycaemic and hyperinsulinaemic clamps, Samms et al., 2017 (111) subsequently 
demonstrated that insulin rather than glucose per se increases both the total and the 
bioactive form of FGF21 in the postprandial period in humans. This supports observations 
from earlier cross-sectional studies showing a positive correlation between plasma insulin and 
total FGF21 levels in human subjects (48,113). The Fibroblast Activation Protein (FAP) is a 
serine protease that cleaves and inactivates FGF21 (114). Interestingly, patients with T2D 
have elevated circulating levels of FAP when compared to non-diabetic controls, and this is 
associated with an attenuated ratio of bioactive to total FGF21 in response to an oral glucose 
tolerance test, suggesting that chronic states of insulin resistance may lead to inactivation of 
FGF21 and limit its metabolic effects (111). Indeed, in response to a high fat dietary 
intervention that is known to alter insulin-stimulated substrate utilization in healthy humans, 
the normal induction of circulating FGF21 in response to insulin is attenuated (111). 
Confirming the mechanism by which insulin and/or insulin resistance regulates the hepatic 
secretion of FGF21 and FAP in humans and the subsequent tissue specific actions of FGF21 
require further investigation. Given that patients with T2D have elevated circulating levels of 
FAP, specific inhibitors for FAP in those patients (in combination with FGF21 mimetics) could 
be an appealing therapeutic strategy, particularly as FGF21 was shown to improve some but 
not all aspects of the metabolic syndrome in humans (see text Box 1).  
 
Acute physiological elevations in plasma FFA levels through intravenous infusion of heparin 
and lipid emulsions was shown to produce modest elevation of circulating FGF21 (115), 
although in heathy human volunteers undergoing a lipid tolerance test, acute elevation of 
plasma FFAs was shown to decrease FGF21 (116,117). In contrast, overfeeding with a high fat 
diet for 5 days resulted in a robust increase in circulating levels of FGF21 (118), possibly as a 
compensatory/adaptive mechanism to increased fat oxidation under conditions of energy 
oversupply. This is supported by the observations that short term (6 days) isoenergetic high 
fat diets do not alter fasting levels of either total or bioactive FGF21 (111). Longer-term 
studies of the impact of high-fat diets have not been carried out, but obesity is generally 
associated with high serum FGF21 in humans, suggesting that chronic adiposity may lead to 
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an FGF21 resistant state (48,113). This notion is particularly intriguing given that a common 
SNP in KLB gene (rs2608819), the key co-receptor mediating the tissue sensitivity to FGF21, is 
associated with higher body mass index, and the protein levels of KLB are reduced in the 
adipose tissue of obese humans which may decrease its responsiveness to FGF21 in vivo 
(113,119). However, the hepatic expression of KLB and FGFR1 and FGFR3 are increased in 
obese individuals which, in contrast to adipose tissue, may confer an improved hepatic 
responsiveness to increased FGF21 levels under those conditions. Large-scale RNA-
sequencing studies reveal that mouse KLB gene is predominantly expressed in the liver, 
pancreas and adipose tissue with no KLB expression detected in skeletal muscle (120). In 
humans, beyond the liver and adipose tissue, KLB is detected in breast, bone marrow and 
pancreas (120). It is conceivable that tissue differences at the KLB level between mice and 
humans may contribute to the divergent findings of the metabolic actions of FGF21 described 
for the two species.  
 
In addition to its role as an insulin-dependent postprandial hormone, studies in mice have 
shown that FGF21 suppresses consumption of simple sugars and non-caloric sweeteners but 
not complex carbohydrates, proteins or lipids via signaling through the paraventricular 
nucleus in the hypothalamus (50). Furthermore, FGF21 administration markedly reduces 
sweet and alcohol preference in mice and sweet preference in cynomolgus monkeys. In mice, 
these effects require the FGF21 co-receptor KLB in the CNS and correlate with reductions in 
dopamine concentrations in the nucleus accumbens (85). These actions of FGF21 may 
represent a conserved mechanism among species as genetic studies in humans have shown 
that SNPs in and around the FGF21 gene are associated with macronutrient preference, 
including carbohydrate, fat and protein intake, and alcohol consumption (44,121,122). The 
fact that consumption of dietary carbohydrates (such as fructose and sucrose) may increase 
the fasting levels of FGF21, which in turn may suppress consumption of simple sugars and 
non-caloric sweeteners, likely indicates the presence of a negative feedback hormonal loop 
between the liver and the brain (Figure 2). Interestingly, recent studies have also linked 
variants in the KLB locus with levels of alcohol intake in humans (123). FGF21 has also been 
shown to stimulate water drinking behaviour in mice in response to alcohol; this response is 
dependent upon β-adrenergic signaling (86). Furthermore, injection of recombinant FGF21 
reduces ad libitum intake of alcohol in mice (122), whereas alcohol ingestion acutely and in 
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the form of binge drinking increases plasma FGF21 in fasting humans (122,124). Therefore, it 
is likely that alcohol-induced hepatic secretion of FGF21 serves as an adaptive mechanism 
aiming to inhibit alcohol appetite and stimulate water consumption in humans and therefore 
protect against long-term alcohol induced hepatic injury (124).  
 
FGF21 has also been suggested to act as an exercise-induced myokine as its serum levels are 
elevated in response to whole body submaximal exercise (23,125,126). However, recent 
elegant studies using tissue arteriovenous differences have shown that exercise is a key 
stimulus in inducing hepatic release of FGF21 in humans (Figure 2). Indeed, during 
submaximal exercise most of the release of FGF21 into the systemic circulation occurs 
through the liver rather than skeletal muscle (107). This was confirmed by a recent study 
showing that maximal eccentric contractions do not stimulate the release of either total or 
bioactive FGF21 from human skeletal muscle, whereas its FGF21 protein content is unchanged 
in response to exercise (108). Interestingly, eccentric exercise resulted in significant 
elevations in arterialised and venous concentrations of its regulatory enzyme FAP, with no 
apparent contribution to its release from the exercised leg (Figure 2). These findings raise the 
possibility that increased levels of FAP may play a role in the inactivation of FGF21 during this 
type of exercise. Collectively, the results from the literature suggest that FGF21 may be an 
exercise-induced hepatokine but not myokine and that strategies aiming to minimise the 
release of FAP may be of benefit in maximising the metabolic effects of FGF21, whether 
administered exogenously or produced in response to exercise. FGF21 was first described as 
a key starvation hormone in a variety of animal models. However, recent studies in adult 
humans provide strong evidence that FGFF21 is an insulin-dependent postprandial hormone 
that plays a key role in the consumption of alcohol, water, simple sugars and non-caloric 
sweeteners. Further understanding of the role of FGF21 in macronutrient preference and 
regulation of appetite in humans could be instrumental to uncovering its therapeutic 
potential in obesity, alcoholism, eating disorders, addictive behaviours and other relevant 
disorders. 
 
Concluding Remarks and Future Perspectives 
Nearly two decades of research on FGF21 have identified it as a potent metabolic regulator 
when manipulated acutely by pharmacological means or by genetic approaches (in mice), and 
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have characterised in detail its target tissues, receptor complexes and degradation pathways.  
However, clinical trials with FGF21 analogues in overweight/obese patients with T2D have not 
progressed to Phase 3 because the improvements in circulating lipid profiles have not been 
matched by improvements in glycaemic control and body weight loss. Perhaps the 
therapeutic potential of FGF21 analogues in T2D may be realised when combined with other 
current therapies targeting glycaemic control. However, the emergence of FGF21 as a 
regulator of macronutrient preference both in rodents and humans and its role in the 
protection from fatty liver disease and dyslipidaemia raises the interesting prospect of its 
therapeutic potential in obesity and some of its comorbidities. This is supported by the 
efficacy of FGF21 as a metabolic regulator in seasonal rodents that undergo natural cycles of 
adiposity and weight loss without the presence of metabolic dysfunction. The way forward 
with FGF21 may be to investigate its efficacy in obesity before T2D develops, targeting 
populations with specific polymorphisms that may confer an improved (tissue-specific) 
responsiveness to FGF21 treatment. This strategy may reveal how responsiveness to FGF21 
can be improved and so insulin sensitivity maintained in the long term, reshaping our view of 
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Figure 1. Exposure of Siberian hamsters to short days initiates molt from a summer agouti 
coat to a white winter coat (top), and programs a decrease in appetite and increased 
catabolism of visceral white fat (WAT) and hence body weight loss as a winter survival 
strategy.  This is associated with increased hepatic FGF21 production. Treatment of hamsters 
in the fat summer state with FGF21 induces behavioral and physiological changes that 
resemble the natural short day response, including decreased appetite, promotion of fat 
oxidation rather than carbohydrate oxidation (associated with decreased pyruvate 
dehydrogenase activity in liver: PDC), and increased thermogenic capacity of brown adipose 
tissue (BAT) via upregulation of uncoupling protein 1 (ucp1) and deiodinase II (dio2) gene 
expression. 
 
Figure 2. In this figure, blue arrows depict decreasing (downward) or increasing (upward) 
circulating concentrations of Fibroblast Activated Protein (FAP) and the bioactive form of 
FGF21 (aFGF21). Red ‘stop’ signs denote the absence of secretion in response to exercise. Red 
crosses and black block arrows indicate impairment in relevant biological processes, which 
when accompanied with questions marks indicate outstanding biological questions that 
require further experimentation. 
In healthy humans (left panel), dietary carbohydrates (CHO) increase both the total and 
bioactive form of FGF21 in an-insulin dependent manner, whereas levels of FAP are 
unaffected. Exercise is a key stimulus in inducing hepatic, but not skeletal muscle, release of 
FGF21. Exercise also increases circulating levels of FAP with no apparent contribution from 
skeletal muscle. It remains to be established whether the liver releases FAP in response to 
exercise. Adipose tissue is the key target for the metabolic effects of FGF21. At target tissues, 
FGF21 binds to and activates members of the FGFR superfamily of receptor tyrosine kinases. 
This activation is dependent on obligate co-receptor bKlotho (KLB). FGF21 also markedly 
reduces sweet and alcohol preference via signaling through the paraventricular nucleus in the 
hypothalamus. The fact that consumption of dietary CHO increases the levels of FGF21, which 
in turn may suppress consumption of simple sugars and non-caloric sweeteners, likely 




Obese individuals with the metabolic syndrome and patients with type 2 diabetes (right 
panel) have elevated circulating levels of FAP, and this is associated with an attenuated ratio 
of bioactive to total FGF21 in response to an oral CHO (glucose) tolerance test, suggesting 
that chronic states of insulin resistance may lead to inactivation of FGF21 and limit its 
beneficial metabolic effects. KLB, the key co-receptor mediating the tissue sensitivity to 
FGF21, is associated with higher BMI, and its protein levels are reduced in the adipose tissue 
of obese humans which may further decrease its responsiveness to FGF21. Strategies aiming 
to minimise the release of FAP (either metabolic syndrome- or exercise-induced) may be of 
benefit in maximising the metabolic effects of FGF21. Finally, it remains to be seen whether 
the negative feedback hormonal loop between the liver and the brain, as related to CHO 
consumption and sweet and alcohol preference, is in any way disturbed/impaired in obesity 
and diabetes, and whether it plays a role in appetite regulation under those conditions. 
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